论文部分内容阅读
西利洛尔(CeliProlol)(CEL)是一种新的具有扩血管和β_2受体兴奋作用的心脏选择性β阻滞剂。本文采用双盲、随机、安慰剂对照、交叉试验比较了CEL和阿替洛尔(ATE)对稳定型心绞痛的疗效。16例稳定型劳力性心绞痛病人,先单盲服用安慰剂1周,然后随机给予CEL或ATE各2周。每一治疗末行标准踏车运动试验。
CeliProlol (CEL) is a new cardioselective β-blocker with vasodilator and β 2 receptor agonism. In this study, a double-blind, randomized, placebo-controlled, crossover trial comparing the efficacy of CEL and atenolol (ATE) in patients with stable angina pectoris was conducted. Sixteen patients with stable angina pectoris were treated blindly for 1 week with placebo and then randomly assigned to either CEL or ATE for 2 weeks. Standard treadmill exercise test at the end of each treatment.